AR046600A1 - Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8 - Google Patents
Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8Info
- Publication number
- AR046600A1 AR046600A1 ARP040103863A ARP040103863A AR046600A1 AR 046600 A1 AR046600 A1 AR 046600A1 AR P040103863 A ARP040103863 A AR P040103863A AR P040103863 A ARP040103863 A AR P040103863A AR 046600 A1 AR046600 A1 AR 046600A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- halogen
- optionally substituted
- alkoxy
- Prior art date
Links
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 title 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- -1 1,3-butadienyl Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 125000006267 biphenyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302811A SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046600A1 true AR046600A1 (es) | 2005-12-14 |
Family
ID=29546627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103863A AR046600A1 (es) | 2003-10-23 | 2004-10-22 | Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070249648A1 (enExample) |
| EP (1) | EP1678178A1 (enExample) |
| JP (1) | JP2007509141A (enExample) |
| KR (1) | KR20060088557A (enExample) |
| CN (1) | CN1898239A (enExample) |
| AR (1) | AR046600A1 (enExample) |
| AU (1) | AU2004284028B2 (enExample) |
| BR (1) | BRPI0415613A (enExample) |
| CA (1) | CA2542226A1 (enExample) |
| IL (1) | IL174698A0 (enExample) |
| MX (1) | MXPA06004300A (enExample) |
| NO (1) | NO20062335L (enExample) |
| SE (1) | SE0302811D0 (enExample) |
| TW (1) | TW200528451A (enExample) |
| UY (1) | UY28572A1 (enExample) |
| WO (1) | WO2005040167A1 (enExample) |
| ZA (1) | ZA200603174B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| SE0303090D0 (sv) | 2003-11-20 | 2003-11-20 | Astrazeneca Ab | Novel compounds |
| SE0303541D0 (sv) | 2003-12-22 | 2003-12-22 | Astrazeneca Ab | New compounds |
| AU2005219438B2 (en) * | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| WO2006107254A1 (en) * | 2005-04-04 | 2006-10-12 | Astrazeneca Ab | Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases |
| JP2008534678A (ja) * | 2005-04-04 | 2008-08-28 | アストラゼネカ・アクチエボラーグ | 新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用 |
| JP2008534677A (ja) * | 2005-04-04 | 2008-08-28 | アストラゼネカ・アクチエボラーグ | 新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用 |
| GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| TW200800999A (en) * | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| US8629147B2 (en) | 2005-11-03 | 2014-01-14 | Chembridge Corporation | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| WO2007143745A2 (en) * | 2006-06-09 | 2007-12-13 | Icos Corporation | Substituted phenyl acetic acids as dp-2 antagonists |
| MX2009000475A (es) * | 2006-07-19 | 2009-07-10 | Astrazeneca Ab | Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas. |
| JP2010503675A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体 |
| EP2061796A2 (en) | 2006-09-15 | 2009-05-27 | Schering Corporation | Azetidine and azetidinone derivatives useful in treating pain and disorders of lipid metabolism |
| AR062841A1 (es) * | 2006-09-15 | 2008-12-10 | Schering Corp | Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos |
| WO2008099165A1 (en) * | 2007-02-15 | 2008-08-21 | Astrazeneca Ab | Piperidine derivatives and their use for treatment of ccr8 mediated diseases |
| US8278313B2 (en) | 2008-03-11 | 2012-10-02 | Abbott Laboratories | Macrocyclic spiro pyrimidine derivatives |
| US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8268853B2 (en) | 2009-06-25 | 2012-09-18 | Abbott Laboratories | 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof |
| ES2557895T3 (es) * | 2010-03-19 | 2016-01-29 | Pfizer Inc | Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina |
| US9493474B2 (en) | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| PT2858975T (pt) * | 2012-06-08 | 2019-07-16 | Univ Pittsburgh Commonwealth Sys Higher Education | Inibidores de fbxo3 |
| SI2861566T1 (sl) * | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| WO2015048567A1 (en) * | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Spirocyclic ebi2 modulators |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| US10562869B2 (en) | 2014-03-17 | 2020-02-18 | Remynd Nv | Oxadiazole compounds |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| MX375424B (es) | 2015-07-31 | 2025-03-06 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| MX2019008626A (es) | 2017-01-20 | 2019-09-19 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). |
| JP2020506903A (ja) | 2017-01-23 | 2020-03-05 | ファイザー・インク | Ｍａｇｌ阻害薬としての複素環式スピロ化合物 |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| AR116020A1 (es) | 2018-09-03 | 2021-03-25 | Bayer Ag | COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| AU2019364417A1 (en) * | 2018-10-24 | 2021-05-20 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis |
| CN115989223B (zh) | 2020-07-03 | 2024-09-20 | 南京艾美斐生物医药科技有限公司 | 使用CCR8抑制剂靶向Tregs的方法和组合物 |
| KR20230142745A (ko) | 2021-01-29 | 2023-10-11 | 세딜라 테라퓨틱스, 인크. | Cdk2 억제제 및 그의 사용 방법 |
| TW202309006A (zh) * | 2021-04-30 | 2023-03-01 | 西班牙商塔拉森斯調節公司 | 作為ｓｉｇｍａ配體的新穎吡啶磺醯胺衍生物、其製備方法及用途，以及包含該吡啶－磺醯胺衍生物的醫藥組成物 |
| TW202317560A (zh) | 2021-06-26 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Ｃｄｋ２抑制劑及其使用方法 |
| CA3235270A1 (en) * | 2021-10-13 | 2023-04-20 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
| TW202430180A (zh) | 2022-11-30 | 2024-08-01 | 瑞士商愛杜西亞製藥有限公司 | 作為ccr8調節劑之芳基-及雜芳基-磺醯胺衍生物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4010201A (en) * | 1974-04-12 | 1977-03-01 | The Upjohn Company | Organic compounds |
| US4263317A (en) * | 1979-09-06 | 1981-04-21 | Hoechst-Roussel Pharmaceuticals, Inc. | Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s |
| CN1290251A (zh) * | 1998-02-04 | 2001-04-04 | 万有制药株式会社 | N－酰基环胺衍生物 |
| AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| CA2494962C (en) * | 2002-08-09 | 2011-06-14 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20070021498A1 (en) * | 2004-10-14 | 2007-01-25 | Nafizal Hossain | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity |
-
2003
- 2003-10-23 SE SE0302811A patent/SE0302811D0/xx unknown
-
2004
- 2004-10-21 UY UY28572A patent/UY28572A1/es unknown
- 2004-10-21 CN CNA200480038668XA patent/CN1898239A/zh active Pending
- 2004-10-21 WO PCT/SE2004/001522 patent/WO2005040167A1/en not_active Ceased
- 2004-10-21 AU AU2004284028A patent/AU2004284028B2/en not_active Ceased
- 2004-10-21 KR KR1020067007682A patent/KR20060088557A/ko not_active Withdrawn
- 2004-10-21 US US10/575,525 patent/US20070249648A1/en not_active Abandoned
- 2004-10-21 CA CA002542226A patent/CA2542226A1/en not_active Abandoned
- 2004-10-21 MX MXPA06004300A patent/MXPA06004300A/es unknown
- 2004-10-21 EP EP04793824A patent/EP1678178A1/en not_active Withdrawn
- 2004-10-21 BR BRPI0415613-7A patent/BRPI0415613A/pt not_active IP Right Cessation
- 2004-10-21 JP JP2006536485A patent/JP2007509141A/ja active Pending
- 2004-10-22 TW TW093132291A patent/TW200528451A/zh unknown
- 2004-10-22 AR ARP040103863A patent/AR046600A1/es not_active Application Discontinuation
-
2006
- 2006-03-30 IL IL174698A patent/IL174698A0/en unknown
- 2006-04-20 ZA ZA200603174A patent/ZA200603174B/xx unknown
- 2006-05-23 NO NO20062335A patent/NO20062335L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20062335L (no) | 2006-07-19 |
| MXPA06004300A (es) | 2006-06-05 |
| TW200528451A (en) | 2005-09-01 |
| AU2004284028A1 (en) | 2005-05-06 |
| AU2004284028B2 (en) | 2008-03-06 |
| ZA200603174B (en) | 2007-03-28 |
| SE0302811D0 (sv) | 2003-10-23 |
| JP2007509141A (ja) | 2007-04-12 |
| BRPI0415613A (pt) | 2006-12-05 |
| IL174698A0 (en) | 2006-08-20 |
| EP1678178A1 (en) | 2006-07-12 |
| US20070249648A1 (en) | 2007-10-25 |
| WO2005040167A1 (en) | 2005-05-06 |
| UY28572A1 (es) | 2005-05-31 |
| CN1898239A (zh) | 2007-01-17 |
| CA2542226A1 (en) | 2005-05-06 |
| KR20060088557A (ko) | 2006-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR106755A2 (es) | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos | |
| AR040390A1 (es) | Inhibidores de quinasas de tirosina | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR040286A1 (es) | Proceso para la preparacion de pirimidinas sustituidas | |
| AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR046648A1 (es) | 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli (adp-ribosa) polimerasa | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR059016A4 (es) | Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos. | |
| AR040257A1 (es) | Profarmacos de aminoacidos excitadores | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| AR026487A1 (es) | Derivados de espiro[2h-1-benzopiran-2,4'-piperidina] para el uso en terapia, especificamente para el tratamiento de alteraciones del snc | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| CY1111857T1 (el) | Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης | |
| AR048834A1 (es) | Compuestos derivados de piperidina o tropano; metodos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por quimioquinas (ccr5) | |
| AR084361A1 (es) | Compuestos de aril triazol con actividad antitumoral | |
| AR049405A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
| AR035311A1 (es) | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |